+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cat Allergy - Pipeline Review, H2 2019

  • ID: 4866601
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 27 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ALK-Abello AS
  • Amgen Inc
  • Biomay AG
  • Sementis Ltd
  • MORE
Cat Allergy - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Cat Allergy - Pipeline Review, H2 2019, provides an overview of the Cat Allergy (Immunology) pipeline landscape.

Cat allergy is an allergic reaction to one or more allergens produced by cats. Symptoms include sneezing, runny or stuffy nose, facial pain (from nasal congestion), coughing, chest tightness, shortness of breath and wheezing, watery, red or itchy eyes and skin rash or hives.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Cat Allergy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cat Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cat Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 2 respectively.

Cat Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cat Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Cat Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cat Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cat Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cat Allergy (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cat Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cat Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ALK-Abello AS
  • Amgen Inc
  • Biomay AG
  • Sementis Ltd
  • MORE
Introduction
Report Coverage
Cat Allergy - Overview
Cat Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cat Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cat Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Amgen Inc
Biomay AG
Regeneron Pharmaceuticals Inc
Sementis Ltd
Cat Allergy - Drug Profiles
Allergen for Cat Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-36 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-19081909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tezepelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cat Allergy - Dormant Projects
Cat Allergy - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Cat Allergy, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Cat Allergy - Pipeline by ALK-Abello AS, H2 2019
Table 9: Cat Allergy - Pipeline by Amgen Inc, H2 2019
Table 10: Cat Allergy - Pipeline by Biomay AG, H2 2019
Table 11: Cat Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Table 12: Cat Allergy - Pipeline by Sementis Ltd, H2 2019
Table 13: Cat Allergy - Dormant Projects, H2 2019
Table 14: Cat Allergy - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Cat Allergy, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Routes of Administration, H2 2019
Figure 4: Number of Products by Stage and Routes of Administration, H2 2019
Figure 5: Number of Products by Molecule Types, H2 2019
Figure 6: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ALK-Abello AS
  • Amgen Inc
  • Biomay AG
  • Regeneron Pharmaceuticals Inc
  • Sementis Ltd
Note: Product cover images may vary from those shown
Adroll
adroll